Paper Details

  1. Home
  2. Paper Details

Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study.

Author: BenzaRaymond L, ChannickRichard N, ChinKelly M, Di ScalaLilla, GaineSean, GalièNazzareno, GhofraniHossein-Ardeschir, HoeperMarius M, LangIrene M, McLaughlinVallerie V, PreissRalph, RubinLewis J, SimonneauGérald, SitbonOlivier, TapsonVictor F

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

The study evaluated the French risk assessment approach and REVEAL 2.0 risk calculator for predicting morbidity/mortality in PAH patients. These methods were assessed in the GRIPHON trial, the largest PAH trial to date, to determine their prognostic and predictive value.
Paper Details　
Original Abstract of the Article :
Approaches to risk assessment in pulmonary arterial hypertension (PAH) include the noninvasive French risk assessment approach (number of low-risk criteria based on the European Society of Cardiology and European Respiratory Society guidelines) and Registry to Evaluate Early and Long-term PAH Diseas...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.healun.2019.12.013

データ提供：米国国立医学図書館（NLM）

Pulmonary Arterial Hypertension: Navigating a Complex Desert

Pulmonary arterial hypertension (PAH), a serious condition that affects the heart and lungs, is like a vast and complex desert, filled with challenges and uncertainties. This research explores different approaches to risk assessment in PAH, examining the prognostic and predictive value of these methods. The researchers meticulously analyzed data from the GRIPHON study, a large randomized controlled trial, to evaluate the accuracy and effectiveness of different risk assessment tools. Their findings offer insights into the best approaches for identifying and managing PAH risk, guiding healthcare providers towards a more effective and personalized approach to patient care. This research is like an explorer's journey across a treacherous landscape, seeking to map the complexities of PAH and its risks.

Finding the Right Path: Risk Assessment in PAH

This research highlights the importance of using comprehensive and accurate risk assessment tools in managing PAH. The study compares the effectiveness of the French risk assessment approach and the REVEAL 2.0 risk calculator in predicting morbidity and mortality in PAH patients. This is like navigating a complex desert, where understanding the terrain and its potential hazards is crucial for survival.

Navigating the Dunes of Risk: Personalized Care

This research emphasizes the importance of individualizing risk assessment and treatment strategies for PAH patients. By using the most accurate and effective risk assessment tools, healthcare providers can tailor treatment plans to meet the unique needs of each patient, improving their overall outcomes and quality of life. This research is like a compass, guiding healthcare providers towards a more personalized and effective approach to managing PAH.

Dr. Camel's Conclusion

This research provides valuable insights into the importance of risk assessment in managing PAH. By comparing different methods and evaluating their effectiveness in predicting morbidity and mortality, the study highlights the need for accurate and comprehensive risk assessment tools to guide individualized treatment strategies. This research is like a roadmap, guiding healthcare providers towards a more effective and patient-centered approach to managing this challenging condition.

Date :
  1. Date Completed 2021-05-06
  2. Date Revised 2023-08-11
Further Info :

Pubmed ID

32061506

DOI: Digital Object Identifier

10.1016/j.healun.2019.12.013

Related Literature

Article Analysis
・Effects of selexipag
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.